Parametric Portfolio Associates’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Parametric Portfolio Associates’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$422K	Sell	9,156 -6,383	-41%	-$344K	﹤0.01%	3162
2021 Q4	$1.31M	Buy	15,539 +2,014	+15%	+$156K	﹤0.01%	2669
2021 Q3	$901K	Sell	13,525 -413	-3%	-$23.8K	﹤0.01%	2842
2021 Q2	$742K	Buy	13,938 +4,923	+55%	+$264K	﹤0.01%	2909
2021 Q1	$391K	Buy	+9,015	New	+$388K	﹤0.01%	3607

Other funds holding ZNTL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Parametric Portfolio Associates's ZNTL Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Zentalis Pharmaceuticals (ZNTL) stake by 41% in Q1 2022, selling an estimated $344K and leaving 9,156 shares worth $422K. The position accounts for ﹤0.01% of the portfolio, ranked #3162.

Parametric Portfolio Associates first reported a position in ZNTL in Q1 2021 and has held it in 5 quarters since. The position peaked at $1.31M in Q4 2021. 129 funds tracked by Wall St. Rank hold ZNTL as of Q1 2022.

Parametric Portfolio Associates held 9,156 shares of Zentalis Pharmaceuticals worth $422K as of Q1 2022.
Parametric Portfolio Associates sold 6,383 Zentalis Pharmaceuticals shares in Q1 2022, an estimated $344K.
Zentalis Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3162 holding.
Parametric Portfolio Associates first reported a position in Zentalis Pharmaceuticals in Q1 2021 and has held it in 5 quarters since.
Parametric Portfolio Associates's Zentalis Pharmaceuticals position peaked at $1.31M in Q4 2021.
129 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.